Summary
Abbott Laboratories reported a solid financial performance for the fiscal year ending December 31, 2024, driven by robust growth across its Medical Devices, Established Pharmaceutical Products, and Nutritional Products segments. The Medical Devices segment, in particular, demonstrated strong momentum with double-digit growth in key areas such as Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure, bolstered by product approvals and expanded indications. The company's recovery in its U.S. Pediatric Nutrition business following a 2022 recall has been significant, with market share gains contributing to overall segment growth. Despite a continued decline in COVID-19 testing-related sales, which is a secular trend, Abbott's core businesses showed resilience. The company's focus on innovation and strategic acquisitions, such as Bigfoot Biomedical and Cardiovascular Systems, Inc. (CSI), are strengthening its product portfolio and market position. Abbott also demonstrated a commitment to shareholder returns by increasing its quarterly dividend and continuing share repurchases. While the company faces ongoing regulatory scrutiny and potential market challenges, its diversified business model and strong product pipeline position it for sustained growth.
Financial Highlights
51 data points| Revenue | $41.95B |
| Cost of Revenue | $18.71B |
| Gross Profit | $23.24B |
| R&D Expenses | $2.84B |
| SG&A Expenses | $11.70B |
| Operating Expenses | $35.13B |
| Operating Income | $6.83B |
| Net Income | $13.40B |
| EPS (Basic) | $7.67 |
| EPS (Diluted) | $7.64 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Medical Devices segment experienced robust growth, led by double-digit increases in Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure.
- 2Diabetes Care sales, driven by continuous glucose monitoring (CGM) systems, reached $6.4 billion, reflecting an 18.1% increase.
- 3U.S. Pediatric Nutritionals sales saw a significant increase of 11.7%, indicating successful market share recovery post-recall.
- 4Established Pharmaceutical Products segment sales grew by 9.2% (excluding foreign exchange), with strong performance in emerging markets.
- 5The company completed key acquisitions, including Bigfoot Biomedical and Cardiovascular Systems, Inc. (CSI), to bolster its product offerings.
- 6Abbott increased its quarterly dividend by 7.3% to $0.59 per share, reflecting confidence in its financial health.
- 7Despite a decrease in COVID-19 testing sales ($747 million in 2024), overall net sales grew by 4.6% year-over-year.